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Endometrial mesenchymal stem cells (eMSC) drive the extraordinary regenerative
capacity of the human endometrium. Clinical application of eMSC for therapeutic
purposes is hampered by spontaneous differentiation and cellular senescence upon
large-scale expansion in vitro. A83-01, a selective transforming growth factor-β receptor
(TGFβ-R) inhibitor, promotes expansion of eMSC in culture by blocking differentiation
and senescence, but the underlying mechanisms are incompletely understood. In this
study, we combined RNA-seq and ATAC-seq to study the impact of sustained TGFβ-
R inhibition on gene expression and chromatin architecture of eMSC. Treatment of
primary eMSC with A83-01 for 5 weeks resulted in differential expression of 1,463
genes. Gene ontology analysis showed enrichment of genes implicated in cell growth
whereas extracellular matrix genes and genes involved in cell fate commitment were
downregulated. ATAC-seq analysis demonstrated that sustained TGFβ-R inhibition
results in opening and closure of 3,555 and 2,412 chromatin loci, respectively. Motif
analysis revealed marked enrichment of retinoic acid receptor (RAR) binding sites,
which was paralleled by the induction of RARB, encoding retinoic acid receptor beta
(RARβ). Selective RARβ inhibition attenuated proliferation and clonogenicity of A83-01
treated eMSC. Taken together, our study provides new insights into the gene networks
and genome-wide chromatin changes that underpin maintenance of an undifferentiated
phenotype of eMSC in prolonged culture.
Keywords: endometrium, mesenchymal stem cell, human, chromatin, gene regulatory networks, transforming
growth factor receptor beta, retinoic acid receptor beta
INTRODUCTION
The human endometrium is a highly dynamic tissue that generates 4–10 mm of mucosa in each
menstrual cycle (Jabbour et al., 2006). This extraordinary regenerative capacity is mediated by
resident epithelial progenitors and mesenchymal stem/stromal cells (MSC) (Chan et al., 2004;
Gargett et al., 2016). Cultured endometrial MSC (eMSC) are clonogenic, highly proliferative,
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multipotent, and express the International Society for Cellular
Therapies (ISCT) surface markers (Gargett et al., 2009). Human
eMSC can be purified as CD140b+CD146+ cells (Schwab and
Gargett, 2007), or by means of the surface marker SUSD2 (Sushi
Domain-containing 2, formerly W5C5) (Masuda et al., 2012).
While eMSC also express Stro-1, this marker does not enrich
for clonogenic cells (Schwab et al., 2008). eMSC further express
MSCA-1 (Sobiesiak et al., 2010). These markers identify eMSC as
pericytes and perivascular cells of endometrial spiral arterioles,
arterioles and venules (Gargett and Masuda, 2010; Murakami
et al., 2014; Lucas et al., 2016; Bozorgmehr et al., 2020). A major
advantage of the endometrium over other sources of adult
MSC, such as bone marrow or adipose tissue, is its accessibility.
Endometrial sampling is a routine office-based procedure that
does not require anesthesia (Gargett and Masuda, 2010).
Preclinical animal studies showed that eMSC are a promising
cell source for treatment of gynecological disorders, including
pelvic organ prolapse (Darzi et al., 2016; Gargett et al., 2019).
For example, eMSC seeded or bio-printed onto meshes with
biomechanical properties matching the human vagina (e.g., non-
degradable polyamide/gelatin composite meshes) (Ulrich et al.,
2014; Emmerson et al., 2019), or on degradable nanofibers
(Mukherjee et al., 2019b; Paul et al., 2019), promote angiogenesis,
collagen deposition, and cellular infiltration into biomaterials
when transplanted into rodent or ovine models. They also elicit
an early inflammatory response, characterized first by influx of
M1 macrophages, which then switch to the M2 wound healing
phenotype (Ulrich et al., 2014; Darzi et al., 2018). In vitro, eMSC
seeded on polyamide/gelatin meshes differentiate into smooth
muscle cells and fibroblasts; cell types that are important for
restoring vaginal structure and function (Su et al., 2014). Hence,
the endometrium is a rich source of MSC for autologous and
allogenic cell-based therapies, including pelvic organ prolapse,
urinary incontinence, and regeneration of scarred endometrium
in women with Asherman’s syndrome (Ulrich et al., 2013; Gargett
et al., 2016; Simoni and Taylor, 2018).
Clinical application of eMSC requires expansion of cells in
culture (Gurung et al., 2015; Darzi et al., 2016). As is the case for
MSC from other sources (Baxter et al., 2004), eMSC cultured over
several passages differentiate spontaneously into endometrial
stromal fibroblasts as shown by signature gene profiles and are
subjected to replicative stress caused by telomere shortening
(Gurung et al., 2015, 2018b; Barragan et al., 2016). Consequently,
the cells lose their proliferative capacity as well as the ability
to reconstitute tissue in vivo (Baxter et al., 2004). To overcome
this impediment to the clinical translation, we and others have
explored the use of small molecules to maintain the in vivo
properties of eMSC and MSC in prolonged culture (Al-Habib
et al., 2013; Gurung et al., 2015, 2018b). In particular, we focused
on blocking the TGFβ receptor signaling pathway as it is one
of the main pathways inducing MSC differentiation (Ng et al.,
2008). A83-01 is also used to prevent spontaneous differentiation
of human pluripotent stem cells (Li and Ding, 2010) and organoid
cultures for a range of epithelial cell types (Sato and Clevers,
2013). We recently reported that A83-01, a selective inhibitor
of TGF-β type I receptor (TGFβ-R) ALK4, 5 and 7 kinase,
increases proliferation and inhibits apoptosis and senescence of
cultured eMSC, thereby safeguarding their functional properties
in vitro (Gurung et al., 2015, 2018b) and prolonging their survival
in vivo (Gurung et al., 2018a). Further, A83-01-treated eMSC
maintain multipotency, exhibit increased angiogenic activity,
express a proangiogenic, antifibrotic, and immunomodulatory
gene profile and enhanced secretory profile of angiogenic and
immunomodulatory factors (Gurung et al., 2015, 2018b).
The mechanisms underlying the expansion of cultured eMSC
in response to sustained TGFβ-R inhibition are incompletely
understood. Adult stem/progenitor cells have more open
chromatin than their differentiated progeny, but less than
pluripotent stem cells. Further dynamic chromatin changes
underpin subsequent differentiation into mesodermal lineages
(Chen and Dent, 2014), including fibroblasts. Based on these
observations, we hypothesized that sustained TGFβ-R inhibition
leads to divergence in the chromatin landscape of cultured
eMSC and activation of transcriptional regulatory circuitries that
maintain the cells in a more naïve or undifferentiated state.
To test this hypothesis, eMSC cultured with or without A83-
01 were subjected to integrated RNA-sequencing (RNA-seq) and
Assay for Transposase Accessible Chromatin through sequencing
(ATAC-seq). Our findings provide new insights into the
mechanisms of action of TGFβ-R inhibition that may lead to the
development of more targeted pharmacological approaches for
eMSC expansion, thereby enhancing their functional properties
for clinical translation.
MATERIALS AND METHODS
Endometrial Biopsies
The study was approved by the Monash Health and
Monash University Human Research Ethics committees.
Endometrial biopsies were obtained from seven pre-menopausal
women, without endometrial pathologies, following written
informed consent and according to The Declaration of
Helsinki (2000) guidelines. Participant information is kept
confidential and samples deidentified prior to use. None of
the participants received hormonal treatment within 3 months
prior to the biopsy.
eMSC Isolation and Culture
Endometrial biopsies were processed and single-cell suspensions
of eMSC obtained as described previously (Masuda et al., 2012).
Briefly, finely minced endometrial tissue was enzymatically and
mechanically digested in Dulbecco’s modified Eagle’s medium
(DMEM/F12) supplemented with collagenase type I and DNase
I (Worthington Biochemical Corporation, United States) at
37◦C on a rotating MACSmix (Miltenyi Biotec, United States)
for 60 min. The digested tissue was filtered through 40 µm
strainers (Becton Dickinson, BD, United States) to remove
gland fragments, washed, red blood cells removed using
Ficoll-Paque (GE healthcare Bio-science, United States) density
gradient separation at 1500 rpm for 15 min, and the interface
containing stromal cells was washed in DMEM/F12/10% fetal calf
serum (FCS, Invitrogen, United States) and 1% primocin (Life
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Technologies, United States). Single-cell suspensions were re-
suspended in separation buffer (0.5% FCS/PBS), and incubated
with 10 µg/ml phycoerythrin (PE)-conjugated anti-human
SUSD2 (BioLegend, United States) in the dark at 4◦C for 30 min.
Cells were then washed, the cell pellet re-suspended in 20 µl
of anti-PE magnetic-activated cell sorting (MACS) microbeads
(Miltenyi Biotec) with 80 µL separation buffer and incubated in
the dark at 4◦C for 30 min. The cells were washed, re-suspended
in separation buffer 500 µL and applied to a Miltenyi column
(Miltenyi Biotech) in a magnetic field. Columns were washed
three times with buffer. Magnetically labeled SUSD2+ eMSC were
eluted with buffer and cell number was determined using Koya
glasstic slides (KOVA International, United States).
eMSC were cultured in DMEM/F12 medium containing
10% FCS, 1% primocin and 2 mM glutamine (Invitrogen),
supplemented with 10 ng/ml basic fibroblast growth factor
(bFGF) (Peprotech, United States) and scaled-down to an
in-house DMEM/F12 serum free medium (SFM) over 48 h
within the first passage and incubated at 37◦C in 5% CO2/5%
O2/90% N2, since this physiological O2 concentration favored
eMSC expansion as described previously (Rajaraman et al.,
2013), with 1 µM TGFβ-R inhibitor, A83-01 (Tocris Bioscience,
United States) or vehicle control (0.01% DMSO). Cells were
seeded at 5,000 cells/cm2 with medium changed every 48 h
and passaged on days 15, 22, 29, and 36 into fibronectin-
coated (10 µg/ml; BD, United States) culture flasks as described
previously (Gurung et al., 2015). At each passage, cells were
counted using Kova glasstic slides and cumulative cell population
(total cell number) calculated by multiplying total number of cells
yielded at the current passage by total number of cells yielded at
the previous passage and then dividing by the number of cells
seeded at the current passage, as described previously (Gargett
et al., 2009). At passage 4 (i.e., 36 days in culture), untreated
and A83-01-treated eMSC cultures were subjected to functional
assays, and RNA- and ATAC-seq.
Flow Cytometry
The surface phenotype of untreated and A83-01-treated eMSC
was assessed by flow cytometry for three MSC markers
[SUSD2, CD140b (Platelet-derived growth factor receptor β)
and CD90 (Thy-1)] as described previously (Gurung et al.,
2015). Cells were incubated for 1 h with 1:20 primary or
matched isotype control antibodies in PBS containing 2% FCS
at 4◦C in dark. The primary antibodies were APC-conjugated
SUSD2 (Biolegend), PE-conjugated CD140b (R&D Systems,
United States) and APC-conjugated CD90 (BD Pharmingen,
United States). Cells were washed with 2% FCS/PBS and fixed
with 1:1 4% paraformaldehyde in 2% FCS/PBS. eMSC were
analyzed using BD FACSCanto II (BD) (10,000 events/sample)
and FlowJo v.10 software.
Colony-Forming Unit-Fibroblast (CFU-F)
Assay
eMSC were cultured with or without A83-01 for 3 passages
(36 days) and then seeded at 50 cells/cm2 to assess cloning
efficiency as described previously (Gurung et al., 2015), with
minor modifications. Briefly, eMSC were seeded on fibronectin-
coated 10 mm culture dishes and cultured in SFM, supplemented
with bFGF and EGF (both 10 ng/mL; Invitrogen), in the presence
or absence of A83-01 (1 µM) in SFM at 37◦C in 5% CO2, 5%
O2, 90% N2 for 2 weeks, with weekly medium changes. Cultures
were then fixed in 10% formalin and stained with hematoxylin
(Amber Scientific, United States), washed and blued in Scott’s tap
water. Colonies were counted and colony efficiency determined
by dividing total number of colonies by number of cells seeded
and multiplied by 100.
RNA Extraction, RNA Quality Control and
RNA Libraries
Total RNA was extracted from untreated and A83-01-treated
eMSC using RNeasy Mini kit (Qiagen, Germany) according to
the manufacturer’s instructions, with some variations. Briefly,
eMSC were trypsinised using TrypLETM (Life Technologies),
resuspended in DMEM/F12 containing 5% Albumax II and then
centrifuged at 300 g for 5 min. Cell were lysed with RNeasy
Lysis Buffer, genomic DNA contamination removed with RNase-
free DNase (Qiagen) and RNA eluted with 30–50 µl RNase-free
water. RNA quality was assessed on an Agilent Technologies
2100 Bioanalyzer according to the manufacturer’s instructions.
Samples with RNA Integrity Number (RIN) > 8 were subjected
TruSeq Poly-A mRNA Library Pro Kit protocol 15031047 RevD
(Illumina, United States) to generate indexed cDNA libraries. The
library size was assessed on an Agilent Bioanalyzer and quantified
by Qubit and qPCR.
RNA-Seq
RNA libraries were sequenced by Illumina HiSeq3000. Fifty
million single-end reads were sequenced per sample with a read
length of 50 bp. Transcriptomic maps were identified using
Bowtie-2.2.3 (Langmead and Salzberg, 2012) and Samtools-1.2.0
(Li et al., 2009) against the UCSC hg19 transcriptome reference
from the Illumina iGenomes resource. Counts were assessed
using HTSeq -0.6.1 (Anders et al., 2015) and transcripts per
million (TPM) were calculated. DESeq2 (Anders and Huber,
2010) was used for detection of differentially expressed genes in
a pair-wise manner. Differentially expressed genes were subjected
to Gene Ontology (GO) and KEGG Pathway enrichment analyses
using the Database for Annotation, Visualization and Integrated
Discovery (DAVID) version 6.8 (Huang da et al., 2009) and
visualized using Reduce and Visualize Gene Ontology (REVIGO)
online software (Supek et al., 2011). Fastq, metadata spreadsheet
and table of counts have been deposited in the National Centre for
Biotechnology Information Gene Expression Omnibus/sequence
Read Archive with GEO (NCBI) accession number SuperSeries
GSE146067/SubSeries GSE146066.
ATAC-Seq
ATAC-seq was performed as described (Buenrostro et al., 2013),
although with some modifications (Vrljicak et al., 2018). Briefly,
cells were washed with cold PBS, lysed using cold EZ lysis
buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2
and 0.1% IGEPAL CA-630, Sigma-Aldrich, United Kingdom),
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transferred to chilled nuclease-free tubes, vortexed, left on ice
for 5 min, and then pelleted in a refrigerated centrifuge. The
nuclear pellet was washed in EZ lysis buffer and re-suspended
in the transposase reaction mix containing 25 µl Tagment DNA
(TD) Buffer, 5 µl Tagment DNA Enzyme and 20 µl nuclease
free water (Nextera DNA Sample Preparation Kit, Illumina,
United Kingdom) for 45 min at 37◦C. Samples were purified
using a Zymo DNA Clean and Concentrator-5 Purification kit
(Zymo Research, United States). Briefly, DNA binding buffer
was added to 50 µl samples, mixed and transferred to the
column, centrifuged at 17,000 g for 30 s at RT, 200 µl DNA
wash buffer added, columns centrifuged and repeated twice. After
removing the residual liquid, 23 µl pre-warmed elution buffer
was added and incubated for 2 min at RT, then centrifuged
for 2 min to elute DNA. Twenty µl samples were added to
PCR tubes containing 5 µl index 1, 5 µl index 2, 15 µl
Master mix (NPM), 5 µl Primer Cocktail (Nextera DNA Sample
Preparation Kit and Nextera Index Kit, Illumina). Amplification
was performed in a Veriti 96 Well Thermal Cycler (Applied
Biosystems, United States) using the following PCR conditions:
72◦C for 3 min, 98◦C for 30 s then 15 cycles of 98◦C for 10 s, 63◦C
for 30 s, 72◦C for 1 min. Libraries were purified using AMPure
XP beads using the Illumina Nextera kit recommended protocol
and quantified using Qubit HS DNA Assay on a Qubit 2.0
Fluorometer. Library sizes were assessed by Agilent Bioanalyzer
using the High Sensitivity DNA chip. ATAC-seq library samples
were sequenced on an Illumina HiSeq 1500 to a depth of
thirty million paired-end reads/sample, with a read length of
100 bp. ATACseq data from this study have been deposited
in the GEO (NCBI) under the accession number SuperSeries
GSE146067/SubSeries146065.
ATAC-Seq Data and Motif Analyses
Sequenced paired-end reads were aligned to the University
of California Santa Cruz (UCSC) human genome 19 (hg19)
assembly using Bowtie2-2.2.6 (Langmead and Salzberg, 2012)
and Samtools-1.2.0 (Li et al., 2009) and peak calling performed
using MACS-2.1.0. HTSeq-0.6.1 (Anders et al., 2015) to count
the reads overlapping the peaks and differential expression
analysis of sequencing data 2 (DESeq2) was used to determine
opening and closing regions of the chromatin (Anders and
Huber, 2010). Fastq, metadata spreadsheet and table of counts
have been deposited in the National Centre for Biotechnology
Information Gene Expression Omnibus/sequence Read Archive
with GEO accession number GSE146065. Differential open
chromatin regions were mapped to cis-regulatory elements of
their proximal genes using ENCODE DNaseI hypersensitivity
data (Thurman et al., 2012). Physical interaction and distance
no greater than 10 kb were used as criteria to assess association
between ATAC-seq peak and proximal gene regulatory element.
De novo short sequence motif analysis using Hypergeometric
Optimization of Motif Enrichment (HOMER) v.4.8 was
performed on 3,555 opening and 2,412 closing ATAC-seq
peaks to determine enrichment and depletion of TF short
sequence binding motifs in the differential ATAC-seq peaks
(Heinz et al., 2010).
RARβ Inhibition Experiments
Passage 3 cultured eMSC from 4 biological samples were treated
with 1 µM A83-01 or 0.01% DMSO (vehicle control) for 7 days,
then trypsinized and seeded in triplicate at 1000 cells/well
(3.125 × 103 cells/cm2) into fibronectin-coated wells of two 96
well plates per biological replicate to assess proliferation on day 0
(D0) and day 3 (D3) in the presence or absence of 10 µM RARβ
antagonist LE135 (Tocris Bioscience) using the cell viability MTS
assay. After seeding, cells were allowed to adhere for 1 h before
addition of 100 µl medium containing A83-01 + LE135 or
A83-01 + DMSO. After 2 h, the MTS reagent (20 µl, CellTiter
96 AQueous One Solution Cell Proliferation Assay, Promega,
United States) was added to wells for the D0 timepoint and
incubated for 2.25 h in the dark, then absorbance read at 490 nm
on a spectrophotometer (Spectramax i3, Molecular Devices,
United States). The medium was changed on the D3 plate at
24 h and the viability assay completed 72 h after seeding, as
described above. Parallel cultures were subjected to CFU-F assays.
Data were corrected for background readings (medium only) for
each plate and normalized to D0 A83-01 for each sample and
reported as fold-change.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism 8.
Technical replicates were inspected for outliers, which were
removed from the analysis using Grubbs test. Normality of
the data was determined with Shapiro–Wilk normality test.
Individual data points and mean ± standard error of the mean
(SEM) are shown when appropriate. Statistical significance was
determined using two-way analysis of variance (ANOVA) or ratio
paired t-tests with p< 0.05 considered statistically significant. For
RNA-seq data analysis, statistical significance was assessed using
the Benjamini–Hochberg procedure to control false discovery
rate. Changes in gene expression were deemed statistically
significant if the adjusted p-value (q-value) was less than 0.05.
RESULTS
Phenotypic Characterization of
Sustained A83-01-Treated eMSC
We previously demonstrated that late passage eMSC cultured
for just 7 days with the TGFβ-R signaling pathway inhibitor,
A83-01, in SFM retain their SUSD2+ phenotype and function
(Gurung et al., 2015). Apoptosis and senescence were prevented
in these short term A83-01-cultured eMSC. To investigate if
eMSC can be expanded more efficiently when maintained under
sustained TGFβ-R inhibition from culture initiation, cells isolated
from 3 individual biopsies were seeded at 5000 cells/cm2 in
SFM supplemented with either A83-01 or vehicle (DMSO).
The medium was refreshed every 48 h and cumulative cell
population calculated at each passage (culture days 15, 22,
29, and 36). As shown in Figure 1A, treatment of eMSC
with A83-01 from culture initiation progressively conferred a
proliferative advantage. After 36 days in culture, at least one
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FIGURE 1 | Sustained TGFβ-R inhibition modulates eMSC function and phenotype in culture. Primary human eMSC, isolated using SUSD2 magnetic bead sorting,
were cultured with or without 1 µM A83-01 in 5% O2 for 36 days. (A) Cumulative cell population in eMSC cultures. Data are mean ± SEM; *p < 0.05. Note the
logarithmic scale of the Y-axis. (B) Clonogenicity of 3 independent MSC cultures following 36 days culture in SFM with and without A83-01. Surface phenotype
assessed by flow cytometry of eMSC cultures after 36 days with or without A83-01 shown as (C) % positive cells and (D) MFI for CD90, CD140b and SUSD2. Data
are mean ± SEM of n = 4 (except for CD140b where n = 3) individual eMSC lines. Individual samples are shown in as different colored data points. *p = 0.039 from
control.
order of magnitude more cells were produced in the A83-
01 medium when compared to control medium (Figure 1A).
Next, we performed colony-forming unit-fibroblast (CFU-F)
assays on eMSC first cultured with or without A83-01 for
3 passages (36 days) and then seeded at a low density (50
cells/cm2) to allow colony formation for a further 14 days. In
keeping with our previous study (Gurung et al., 2015), exposure
of cultured eMSC to A83-01 increased the CFU-F activity of
primary cultures between ∼ 4-10-fold (p = 0.0146; Figure 1B).
We then chose the 36-day timepoint (Figure 1A) to analyze
A83-01-treated cells for the expression of phenotypic eMSC
markers CD140b, SUSD2, and CD90 as a representative ISCT
marker, by flow cytometry. The abundance of CD90+ cells
was 99.1 ± 0.5% (n = 4) for the control and did not change
upon TGFβ-R blockade (99.7 ± 0.2%, n = 4) (Figure 1C).
Similarly, CD140b did not change following prolonged A83-
01 treatment (81.7 ± 10.7% vs. 98.9 ± 0.5% (n = 3). In
contrast, A83-01 treatment increased the abundance of SUSD2+
cells from 49.8 ± 9.2% to 74.1 ± 9.4% (n = 4, p = 0.011)
(Figure 1C). Mean fluorescence intensity (MFI) was also
calculated to evaluate the abundance of different cell surface
molecules/cell. The MFI for CD90, CD140b and SUSD2 did not
increase (Figure 1D) in response to prolonged A83-01 treatment,
although there was a trend for SUSD2 (1108± 269 vs. 1907± 516,
n = 4, p = 0.089).
Transcriptional Profiling of Sustained
A83-01-Treated eMSC
To explore how cultured eMSC are maintained in a more
naïve state upon sustained TGFβ-R inhibition, three independent
cultures treated with or without A83-01 for 36 days were
subjected to RNA-seq. Principal component analysis revealed
that the greatest variation in gene expression is accounted for
by intrinsic differences between primary cultures. The effect of
A83-01 treatment was apparent in principal component 2 (PC2),
which accounted for 28% of the variance in gene expression
(Figure 2A). Following Benjamini–Hochberg correction for
multiple testing, 1,463 genes were differentially expressed upon
A83-01 treatment (Figure 2B), 759 (52%) of which were up-
regulated and 704 (48%) down-regulated. Gene ontology (GO)
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FIGURE 2 | Transcriptomic profile of eMSC upon sustained A83-01 treatment. (A) Principal component analysis of RNA-seq data from three independent primary
eMSC cultures treated with or without TGFβ-R inhibitor for 36 days. (B) Average gene expression levels expressed as log2 transformed counts normalized to library
size between control and A83-01 treated libraries. Red dots represent significantly differentially expressed genes (q < 0.05), black dots indicate non-differentially
expressed genes. (C) Semantic clustering of significantly overrepresented GO terms (p < 0.05) of differentially induced and repressed genes (left and right panel,
respectively) upon A83-01 treatment. The color key is shown on the right. The most highly enriched GO categories are indicated in blue. The size of the circles
reflects the frequency of the GO term. (D) Enrichment analysis of KEGG pathways associated with up- and down-regulated genes (left and right panels, respectively).
analysis using DAVID revealed that genes induced upon A83-
01 treatment are enriched in 61 biological processes, including
‘regulation of cell growth’ (p = 7.8 × 10−4) and ‘intracellular
receptor signaling pathways’ (p = 4.5 × 10−4) (Figure 2C,
left panel). Conversely, analysis of downregulated genes yielded
GO terms such as ‘cell fate commitment’ (p = 4.9 × 10−4),
‘collagen catabolism’ (p = 1.7 × 10−13), and ‘collagen fibril
organization’ (p = 4.6 × 10−6) (Figure 2C, right panel).
Notably, 20 out of the 43 most significantly down-regulated
genes in A83-01 treated eMSC encode extracellular matrix (ECM)
components, including various collagen subunits (e.g., COL1A1,
COL1A2, COL4A1, COL4A2, COL5A1, COL5A2, COL6A3, and
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COL8A1), secreted protein acidic and cysteine rich (SPARC),
and fibronectin (FN) (Supplementary Figure S1). Many of
the ECM genes repressed by A83-01 are very highly expressed
in untreated eMSC with levels ranging from 342 to 14,586
TPM (Supplementary Figure S1). These data suggest that the
effect of TGFβ-R blockade on eMSC is mediated, at least in
part, by limiting ECM synthesis and deposition in prolonged
culture. As shown in Supplementary Figure S2, several
angiogenic, anti-inflammatory, immunomodulatory, antifibrotic
and anti-apoptotic genes were significantly upregulated in
A83-01-treated cells, in keeping with our previous report
(Gurung et al., 2018b).
Further annotation of differentially expressed genes using
the KEGG Pathway database underscored the functional
differences between A83-01-treated and untreated cultures
(Figure 2D). Notable pathways enriched in eMSC in response
to sustained TGFβ-R inhibition included the ‘cyclic guanosine
monophosphate (cGMP)-protein kinase G (PKG) signaling
pathway,’ which is implicated in nitric oxide-mediated
cardioprotection during acute ischemic preconditioning
(Sun et al., 2013), cell growth, and inhibition of apoptosis
(Wolfertstetter et al., 2013), and ‘cytokine-cytokine receptor
interaction’, in keeping with the innate paracrine function of
MSC (Tolar et al., 2010; Mukherjee et al., 2019a). Conversely,
A83-01 repressed genes were enriched in ‘pathways in cancer,’
‘focal adhesion,’ and ‘ECM-receptor interaction.’ Notably, the
‘PI3K-Akt signaling pathway’ was common to both up- and
down-regulated genes. This multifaceted pathway controls key
cellular processes by phosphorylating substrates involved in
apoptosis, protein synthesis, metabolism, and cell cycle. Mining
of the RNA-seq data revealed that A83-01 induces several
genes involved in activation of response to oxidative stress
and cellular detoxification pathways, including Prostaglandin-
Endoperoxide Synthase 2 (PTGS2), Cytoglobin (CYGB),
Scavenger Receptor Class A Member 3 (SCARA3), Glutathione
Peroxidase 3 (GPX3), Scavenger Receptor Class A Member 5
(SCARA5) and Apolipoprotein E (APOE). Conversely, multiple
senescence-associated genes, including Cyclin Dependent Kinase
Inhibitor 1A (CDKN1A), Cyclin Dependent Kinase Inhibitor
2B (CDKN2B), Cyclin Dependent Kinase 6 (CDK6), Cyclin
D2 (CCND2), Ataxia Telangiectasia Mutated (ATM), tumor
protein p53 inducible protein 3 (TP53I3) and phosphatase and
tensin homolog (PTEN) were inhibited upon A83-01treatment
(Supplementary Table S1 and Supplementary Figures S3A,B).
Other senescence associated genes, such as Serpin Family E
Member 2 (SERPINE2), and Netrin 4 (NTN4) (Supplementary
Figures S3A,B) were also significantly downregulated. This
gene signature supports the conjecture that continuous TGFβ-R
inhibition during culture expansion leads to the emergence of
senescence-resistant eMSC.
Chromatin Changes Induced by
Sustained A83-01 Treatment of eMSC
Dynamic changes in chromatin structure and epigenetic code
drive gene expression and ultimately define cell identity (Chen
and Dent, 2014). To map the global changes in the genomic
architecture of cultured eMSC in response to sustained TGFβ-
R inhibition, 3 independent eMSC cultures treated with or
without A83-01 for 36 days were subjected to ATAC-seq,
which profiles chromatin accessible regions as a sequencing
depth readout (Vrljicak et al., 2018). Based on q ≤ 0.05,
DESeq identified 5,967 differential ATAC-seq peaks upon A83-
01 treatment, 60% of which involved opening of genomic regions
and 40% closing of specific loci. Out of 5,967 peaks, 31 and
29% of the opening and closing ATAC-seq peaks, respectively,
fell within −10 to +1 kilobases (kb) around transcriptional
start sites (TSSs). RARB (coding retinoic acid receptor beta,
RARβ), TGFBR3 (transforming growth factor beta receptor 3)
and SUSD2 exemplify genes that showed increased chromatin
accessibility at and upstream of their proximal promoters upon
A83-01 treatment (Figure 3A). Cross-referencing with RNA-
seq data showed a significant increase in RARB, TGFBR3
and SUSD2 transcript levels in response to A83-01 treatment
(q = 1.1 × 10−33, q = 1.2 × 10−22, and q = 2.7 × 10−5,
respectively). Conversely, CADM1 (cell adhesion molecule 1),
COL1A1 (collagen type I alpha 1 chain), and WNT5A are
examples of genes repressed in response to A83-01 treatment
(q = 1.9 × 10−46, q = 1.4 × 10−9, and q = 5.0 × 10−30,
respectively). As shown in Figure 3B, downregulation of CADM1
and COL1A1 is associated with closure of their proximal
promoters whereas silencing of WNT5A coincides with closure
of a distal enhancer. Given that A83-01 inhibits senescence
and apoptosis upon expansion of eMSC in culture (Gurung
et al., 2015), we also searched for differential ATAC-seq peaks in
proximal promoters of genes involved in senescence resistance.
For example, A83-01 treatment resulted in opening of the
proximal PGTS2 (prostaglandin endoperoxidase synthase 2)
promoter (q = 5.4× 10−2). On the other hand, loss of chromatin
accessibility to the CCND2 (cyclin D2) promoter (q = 1.1× 10−2)
(Supplementary Figure S3C) was also observed.
The gain or loss of ATAC-seq peaks upon A83-01 treatment
indicates that altered transcription factor (TF) binding drives
differential gene expression. However, both activating and
repressive TFs can potentially bind at different regulatory sites,
rendering it challenging to confidently predict gene expression
from dynamic chromatin changes at specific loci alone (Vrljicak
et al., 2018). Nevertheless, analysis of 200 genes associated
with the most induced or repressed ATAC-seq peaks (within
10 kb of TSSs) revealed a strong association with increased
or decreased expression, respectively, upon A83-01 treatment
(p = 1.0 × 10−6) (Figure 4). Next, we interrogated the ATAC-
seq data to gain insight into the cis- regulatory landscape that
underpins the transcriptional responses of eMSC to sustained
A83-01 treatment from culture initiation. De novo binding motif
enrichment analysis was performed using HOMER on 3,555
opening and 2,412 closing ATAC-seq peaks. This annotation
yielded 19 significantly overrepresented motifs in opening peaks
(Supplementary Figure S4), and 17 overrepresented motifs in
closing peaks (Supplementary Figure S5).
Next, we matched the motifs against canonical TFs that
are differentially expressed in cultured eMSC treated with
and without A83-01 (Figure 5A). CCAAT/enhancer binding
protein beta and delta (CEBPB/CEBPD), RARB, RAR-related
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 September 2020 | Volume 8 | Article 567610
fcell-08-567610 August 30, 2020 Time: 10:1 # 8
Lucciola et al. TGFβ-R Inhibition in Endometrial MSC
FIGURE 3 | Changes in chromatin accessibility in A83-01 treated eMSC. (A) Representative ATAC-seq peaks showing transition from closing to opening chromatin
upstream of the promoter of RARB, TGFBR3 and SUSD2 in response to A83-01. (B) Representative ATAC-seq peaks showing transition from opening to closing
chromatin of the proximal promoter of CADM1 and COL1A, and of a distal enhancer of WNT5A in response to A83-01. Black and red traces represent untreated
and A83-01-treated eMSC cultures. The X-axis shows the genomic location of the ATAC-seq peaks and genes. The Y-axis shows the frequency of Tn5 cutting.
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FIGURE 4 | Differential chromatin opening correlates with gene expression changes in A83-01-treated eMSC. Changes in chromatin landscape of eMSC in
response to TGFβ-R inhibition correlate with differential regulation of gene expression. Box plots showing increase or decrease in transcript levels of 200 genes
(within 10 kb of the TSS) associated with the most open and closed ATAC-seq peaks. Y-axis shows relative changes in transcript levels, expressed as log2-fold
change: +ve and –ve values relate to up- and down-regulated genes, respectively. X-axis shows ATAC-seq peaks clustered in opening and closing peaks. Green
dots represent the genes and the red asterisk represents mean log2-fold change (p = 1.0 × 10-6, t-test).
orphan receptor alpha (RORA), and nuclear receptor subfamily
4 group A member 1 (NR4A1, also known as NUR77) were
amongst the most plausible differentially expressed genes of
TFs that can bind the enriched motifs in opening ATAC-
seq peaks with high affinity (Figures 5A,B). Conversely,
reduced expression of transcription factor 21 (TCF21),
TGFB induced factor homeobox 2 (TGIF2), and nuclear
transcription factor Y subunit alpha (NFYA) paralleled the
loss of their corresponding binding sites in closing loci
(Figures 5A,B).
RARβ Is One Mediator of A83-01
Responses in eMSC
A notable observation was that A83-01 treatment markedly
upregulated RARB expression (q = 1.1 × 10−33) (Figure 5A) in
parallel with genome-wide enrichment of RAR/RORA binding
sites (p = 1.0 × 10−168) (Figure 5B). RARβ is a member of
the thyroid-steroid hormone receptor superfamily of nuclear
transcription regulators. It binds retinoic acid (RA), the
biologically active form of vitamin A (Gudas, 2012). Further,
A83-01 induces multiple other genes implicated in RA signaling
(Figure 6A), including the cellular retinoic acid binding protein
2 (CRABP2), as well as known RA target genes (Figure 6B).
GDF7 (coding growth differentiation factor 7) andMTSS1 (MTSS
I-BAR domain containing 1) exemplify RA target genes that
exhibited increased chromatin accessibility and expression in
A83-01-treated cells (Figure 6C). To explore the effect of RARB
on A83-01-treated eMSC further, we utilized LE135, a selective
RARβ antagonist (Murakami et al., 2013). LE135 had no effect
on eMSC proliferation in standard cultures not treated with
A83-01. However, addition of LE135 to A83-01 treated cultures
indicated that RARβ inhibition partially reverses the proliferation
advantage conferred by TGFβ-R inhibition (Figure 6D). In
addition, LE135 reduced the clonogenicity of A83-01 treated
eMSC (Figure 6E).
DISCUSSION
This study demonstrates that eMSC cultured under continuous
TGFβ-R inhibition from culture initiation are protected
against loss of proliferation and clonogenicity upon long-
term expansion. The impact of A83-01 on the phenotype of
cultured eMSC was underpinned by an altered chromatin
landscape and gene expression. More than 1,400 genes
were differentially regulated by culturing eMSC in A83-01-
containing SFM for 5 weeks, characterized by upregulation of
angiogenic, anti-inflammatory, immunomodulatory, antifibrotic
and antiapoptotic genes and marked downregulation of
ECM genes. The overall signature indicated that A83-01
maintains the expression of genes involved in eMSC paracrine
activity while simultaneously inhibiting activation of fibroblast
differentiation genes. Over 3,500 regions of chromatin opened
while approximately 2,400 genomic loci closed in response
to continuous TGFβ-R inhibition. Motif analysis identified
marked enrichment of several putative TF binding sites
associated with the more undifferentiated A83-01-treated
eMSC, most prominently RAR/ROR. RARB expression was
also markedly upregulated in parallel with multiple genes
encoding signal intermediates in the RA pathway as well as
known RA target genes. Functional assays with a selective RARB
inhibitor demonstrated for the first time an integral role for
RA signaling in effecting eMSC responses to prolonged A83-01
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FIGURE 5 | Motif discovery analysis in dynamic genomic regions. (A) Inhibition of TGFβ-R signaling pathway alters expression of genes encoding TFs. Graph shows
expression of selected significantly up- and down-regulated TFs (log2-fold change ≥ 1 and ≤ -1). (B) Differentially regulated TFs matched to enriched and depleted
short sequence binding motifs. Bar graph showing enriched and depleted binding motifs coupled with the most plausible differentially expressed TFs, based on motif
specificity. In the bar graph, the frequency (%) of peaks (blue bars) containing the motif is shown relative to genomic regions randomly selected from the genome
(orange bars) (±50 kb from TSS, matching size, and GC/CpG content). P indicates the p-value of the short sequence binding motifs.
treatment. Thus, sustained inhibition of TGFβ-R signaling
during eMSC expansion in extended serum-free cultures under
physiological O2 conditions produces a relatively homogeneous,
undifferentiated population of cells with favorable properties for
clinical translation.
We reported previously that short-term treatment with A83-
01 in SFM (7 days) following extensive culture expansion of
eMSC in serum medium (6 passages) increases proliferation
and enhances clonogenicity (Gurung et al., 2015). Here we
report that sustained TGFβ-R inhibition from culture initiation
similarly promotes eMSC clonogenicity and proliferation with
significant differences observed by passage 3. Although eMSC
intrinsically have extensive proliferative capacity in culture, the
use of A83-01 enhances this proliferative capacity, increasing
cellular output for potential clinical translation (Gargett et al.,
2019). Prolonged culture under these conditions also increased
the percentage of SUSD2-expressing cells, but not CD140b or
the representative ISCT marker CD90, nor the density of these
surface markers on the A83-01-treated cells, indicating that the
perivascular eMSC phenotype was retained and spontaneous
fibroblast differentiation attenuated.
We reported previously that the MFI and percentage of cells
positive for certain ISCT surface markers (CD29, CD44, CD73,
CD105) are insensitive to culture conditions (Rajaraman et al.,
2013). This is also the case for CD90. Similar observations have
been reported for adipose, dental pulp, amniotic fluid MSC
(Gharibi and Hughes, 2012) and bone marrow MSC (Haniffa
et al., 2009). Further, ISCT markers do not discriminate between
MSC and differentiated fibroblasts in culture (Haniffa et al.,
2009). Likewise, CD90 is expressed in vivo on human endometrial
fibroblasts as well as eMSC (Schwab et al., 2008), supporting our
in vitro observations. By contrast, we have provided evidence
that more recent bone marrow MSC markers, such as TWIST1,
TWIST2, and JAG1 (Gurung et al., 2018b), are more indicative
of eMSC function. Notably, these marker genes are upregulated
within 1 week of culturing in A83-01-containing medium
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FIGURE 6 | RARβ is one mediator of A83-01 responses in eMSC. (A) A83-01 treatment induces genes implicated in RA signaling and (B) RA downstream target
genes. (C) Examples of RA target genes with increased chromatin accessibility. (D) Inhibition of RARβ using a selective antagonist, LE135, partially reverses the
proliferation advantage gained upon A83-01 treatment and (E) reduces colony forming efficiency. Data in (D,E) are mean ± SEM of fold change over control (shown
as dotted line). Individual samples are shown in as different colored data points. Shared symbols indicate significant differences, p < 0.05.
(Gurung et al., 2018b). Currently, SUSD2 is the most sensitive
marker to distinguish eMSC from endometrial fibroblasts with
the level of expression correlating to the abundance of highly
proliferative and clonogenic eMSC in culture (Murakami et al.,
2014; Gurung et al., 2015; Bozorgmehr et al., 2020).
Our data for eMSC clonogenicity and proliferation also
highlighted intrinsic differences in A83-01 responsiveness
between eMSC cultures established from different donors, a well-
known feature of primary MSC cultures (Gargett et al., 2016).
Recently it was shown that body mass index of patients, but not
age, correlate inversely with the abundance of clonal SUSD2+
eMSC (Murakami et al., 2013). These observations raise the
possibility that clinical variables, such as obesity, impact on the
in vitro expandability of eMSC.
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The divergent expression of a large number of genes in
A83-01-treated cultures suggests either profound transcriptional
reprogramming or – perhaps more likely – attenuation of
fibroblast differentiation cues imposed by in vitro culture
conditions. For example, a striking but not entirely unexpected
observation is that A83-01 represses multiple highly expressed
genes involved in ECM deposition and collagen metabolism,
including 8 collagen subunit genes, FN1, TGFB1 and SPARC.
During normal wound healing, TGFβ signaling is transiently
increased to activate fibroblasts (Massague, 2012). Failure to
terminate TGFβ signaling following tissue repair results in
chronic activation of fibroblasts, massive accumulation of ECM,
and fibrosis. Thus, a likely mechanism of A83-01 actions involves
prevention of illicit fibroblast differentiation and activation in
extended eMSC cultures. In keeping with previous observations
(Gurung et al., 2018b), genes involved in angiogenesis (e.g.,
SLIT2, HPSE, and SFRP1) (Dufourcq et al., 2008; Urbich et al.,
2009; Lv et al., 2018), cell survival (e.g., ENPP2, FAIM2) (Somia
et al., 1999; Vidot et al., 2010), and immunomodulation (e.g.,
TLR3 and IL1R1) (Rameshwar et al., 1997; Farkas et al., 2019)
were also upregulated upon prolonged A83-01 treatment. This
gene profile infers that sustained TGFβ-R inhibition leads to
expansion of perivascular eMSC that are more efficient in
reducing inflammation, promoting wound healing and tissue
growth, and minimizing fibrosis when transplanted in vivo. These
functional properties are considered cardinal features of MSC,
which were recently renamed as Medicinal Signaling Cells to
reflect their paracrine activity (Caplan, 2017).
ATAC-seq analysis revealed that TGFβ-R inhibition in
cultured eMSC modifies chromatin accessibility at almost 6,000
genomic regions. The overall pattern, characterized by more
opening than closing loci, is in keeping with the less differentiated
state of A83-01 treated cells (Chen and Dent, 2014). A strong
correlation was observed between changes in gene expression and
differentially chromatin accessibility of promoter regions. For
example, opening of chromatin at and upstream of the SUSD2
promoter corresponded to increased abundance of SUSD2+
eMSC in A83-01 cultures. Interestingly, SUSD2 has been shown
to prevent senescence and cell death in tumor cells (Zhang
et al., 2017), suggesting its induction is important for expansion
of cultured eMSC.
Furthermore, maintenance of eMSC lifespan during culture
expansion under sustained TGFβR inhibition involves
upregulation of antioxidant pathways and downregulation
of cell cycle arrest pathways that lead to the senescent phenotype
of aging MSC (Martínez-Zamudio et al., 2017; Wiese et al.,
2019; Cakouros and Gronthos, 2020). For example, A83-01
treatment resulted in opening of the proximal PGTS2 promoter
in parallel with increased transcription. By contrast, expression
of multiple transcripts involved in the cyclin-dependent kinase
inhibitor pathway were repressed, including CCND2, which also
showed proximal promoter closing and is associated with MSC
senescence (Bertolo et al., 2019). A83-01 effects on chromatin
architecture and gene expression may also prevent transcriptome
drift that precedes MSC aging (Wiese et al., 2019).
Another potential mechanism that promotes survival of A83-
01-treated eMSC involves closure of the proximal promoter of
CADM1, which encodes a potent inhibitor of cell proliferation
and migration (Murakami, 2005).CADM1 repression is mediated
by TWIST1 (Hartsough et al., 2019), a TF upregulated in eMSC
in response to A83-01 treatment (Gurung et al., 2018b). The
altered cis-regulatory chromatin landscape in response to A83-
01-induced TGFβ-R blockade also suggested that silencing of
specific TFs may be essential to maintain cultured eMSC in
an undifferentiated state. A case in point is the loss of TCF21
binding sites in parallel with marked repression of TCF21
expression. TCF21 is a member of basic helix-loop-helix family
of transcription factors, which orchestrates cell-fate specification,
commitment and differentiation in multiple cell lineages during
development (Acharya et al., 2012). Furthermore, TCF21 has
recently been shown to drive fibrosis associated with ovarian and
deep infiltrating endometriosis (Ganieva et al., 2020).
Our combined RNA- and ATAC-seq analysis identified
the RA pathway as a putative pharmacological target to
modulate eMSC in culture. A83-01 markedly upregulated
RARB expression in parallel with genome-wide enrichment
of putative RORA/RAR binding sites. RA plays an important
role during embryonic and fetal development and fine-tunes
cellular immune response (Mora et al., 2008). In human
endometrium, RA signaling is silenced upon differentiation of
endometrial fibroblasts into specialized decidual cells (Vrljicak
et al., 2018). Induction of RA target genes in A83-01-treated
eMSC confirmed that this signaling pathway is activated
endogenously in response to sustained TGFβ-R inhibition.
Further, the selective RARβ antagonist, LE135, attenuated the
cellular responses to A83-01, indicating that increased or
sustained RA-RARβ signaling protects eMSC against loss of
proliferative capacity and clonogenicity in prolonged culture.
Another putative pharmacological target is NR4A1, an orphan
nuclear receptor highly induced in A83-01 treated cells. This
orphan nuclear receptor exerts pleiotropic regulatory effects on
glucose and lipid metabolism (Pei et al., 2006), inflammatory
responses (Fassett et al., 2012), and vascular homeostasis (Zeng
et al., 2006). Interestingly, NR4A1 inhibits TGFβ signaling in
the nucleus by promoting the assembly of a repressor complex
that binds to the promoters of TGFβ target genes (Palumbo-Zerr
et al., 2015). Because of its role as an endogenous TGFβ inhibitor,
small-molecule NR4A1 agonists are under development for the
treatment of fibrotic disorders (Palumbo-Zerr et al., 2015).
While the present study shows that A83-01-pretreated eMSC
show promise for clinical translation, further research is required
to determine their quality, safety and efficacy profile. This
includes determining the minimal release criteria such as
%SUSD2+ cells, secreted proteins and qRT-PCR of key genes
that predict efficacy of in vivo function of A83-01-pretreated
eMSC. We will also assess the effect of A83-01 withdrawal and
reversibility on global chromatin architectural changes and gene
expression, and the effect on cryopreservation and thawing.
Functional in vivo assays of sustained A83-01-treated eMSC
will be assessed using our xenograft mouse model (Gurung
et al., 2018a) and in tumorigenicity animal models (Sato
et al., 2019). In vitro potency assays that reflect in vivo eMSC
function need to be developed, based on their angiogenic and
immunomodulatory properties.
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In summary, by integrating genome-wide expression and
DNA accessibility profiling techniques, this study has advanced
our understanding of the cis-regulatory DNA landscape and
gene networks that safeguards eMSC against spontaneous
fibroblast differentiation and loss of function in prolonged
cultures. Analyses of these two large data sets revealed novel
pharmacological targets that could be exploited to accelerate
clinical translation of autologous eMSC therapies for a variety
of reproductive disorders. Furthermore, the data sets constitute a
robust resource to interrogate fundamental molecular questions
pertaining to human endometrial biology.
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